We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+18.88%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
-$219M
(-12%)
Cap. Flow
-$413M
Cap. Flow
% of AUM
-25.11%
Top 10 Holdings %
Top 10 Hldgs %
53.34%
Holding
74
New
16
Increased
18
Reduced
15
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$65.6M |
| 2 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$48.9M |
| 3 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$32.5M |
| 4 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$31.9M |
| 5 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$30.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$92.3M |
| 2 |
Zimmer Biomet
ZBH
|
+$77.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$62.1M |
| 4 |
AGN
Allergan plc
AGN
|
+$54.4M |
| 5 |
AbbVie
ABBV
|
+$47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.57% |
| 2 | Consumer Staples | 9.02% |
| 3 | Financials | 4.8% |
| 4 | Materials | 0.45% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Novavax
NVAX
$1.2B
| $23.6M | 1.43% |
230,000
+55,100
| +32% | +$3.89M |
|
|
FPRX
27
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $20.1M | 1.22% |
+1,200,000
| New | +$14.9M |
|
|
CYNO
28
DELISTED
Cynosure, Inc. Class A
CYNO
| $20M | 1.21% |
750,000
+25,000
| +3% | +$601K |
|
|
29
Intuitive Surgical
ISRG
$127B
| $19.4M | 1.18% |
454,086
-1,476,900
| -76% | -$62.1M |
|
30
Exelixis
EXEL
$13.3B
| $19M | 1.15% |
3,100,000
+1,844,650
| +147% | +$10.2M |
|
|
ACGN
31
DELISTED
Aceragen Inc
ACGN
| $15.5M | 0.94% |
24,657
+589
| +2% | +$196K |
|
|
SHPG
32
CALL
DELISTED
Shire pic
SHPG
| $14.1M | 0.86% |
+100,000
| New | +$13.1M |
|
33
Myriad Genetics
MYGN
$270M
| $13.6M | 0.83% |
+650,000
| New | +$16.4M |
|
|
34
Gilead Sciences
GILD
$162B
| $13.1M | 0.8% |
175,000
-1,325,000
| -88% | -$92.3M |
|
35
CALL
Viatris
VTRS
$20.4B
| $13M | 0.79% |
+300,000
| New | +$12.3M |
|
|
RGLS
36
DELISTED
Regulus Therapeutics
RGLS
| $12.9M | 0.79% |
14,583
+6,458
| +79% | +$5.56M |
|
|
ACOR
37
DELISTED
Acorda Therapeutics
ACOR
| $11.7M | 0.71% |
3,333
-1,250
| -27% | -$4.87M |
|
38
Biogen
BIIB
$30B
| $7.77M | 0.47% |
+27,800
| New | +$7.19M |
|
|
MON
39
DELISTED
Monsanto Co
MON
| $7.35M | 0.45% |
63,100
-261,900
| -81% | -$28.6M |
|
40
Teva Pharmaceuticals
TEVA
$40.8B
| $6.62M | 0.4% |
+165,200
| New | +$6.5M |
|
|
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.94M | 0.36% |
98,563
-157,458
| -62% | -$8.56M |
|
42
Merck
MRK
$322B
| $5.71M | 0.35% |
+119,577
| New | +$5.47M |
|
43
HCA Healthcare
HCA
$87.2B
| $5.11M | 0.31% |
+107,000
| New | +$4.95M |
|
|
44
Zimmer Biomet
ZBH
$18.2B
| $4.72M | 0.29% |
52,221
-900,529
| -95% | -$77.9M |
|
|
AGN
45
DELISTED
Allergan plc
AGN
| $4.52M | 0.27% |
26,900
-348,100
| -93% | -$54.4M |
|
46
Abbott
ABT
$183B
| $4.5M | 0.27% |
+117,300
| New | +$4.32M |
|
47
Thermo Fisher Scientific
TMO
$213B
| $2.95M | 0.18% |
26,500
-14,426
| -35% | -$1.43M |
|
|
HMA
48
PUT
DELISTED
HEALTH MGMT ASSOC INC CL-A
HMA
| $2.62M | 0.16% |
+200,000
| New | +$2.59M |
|
|
CSII
49
DELISTED
Cardiovascular Systems, Inc.
CSII
| $1.72M | 0.1% |
+50,000
| New | +$1.45M |
|
|
50
AbbVie
ABBV
$443B
| – | – |
-1,050,000
| Closed | -$47M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2013 Portfolio in Review
As of Q4 2013, HealthCor Management held 74 positions worth $1.65B, down 12% from $1.87B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
HealthCor Management withdrew a net $413M in Q4 2013, closing 25 positions and reducing 15 holdings. Its most notable exit was AbbVie, an estimated $47M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 63% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, HealthCor Management opened a new position in Mead Johnson Nutrition Company worth $50.3M.
- HealthCor Management's largest Q4 2013 buy was Mead Johnson Nutrition Company: 600,000 shares worth $50.3M.
- HealthCor Management added most to McKesson in Q4 2013, an estimated $65.6M increase.
- HealthCor Management's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $92.3M.
- HealthCor Management fully exited AbbVie in Q4 2013, selling an estimated $47M.
- HealthCor Management's ten largest holdings make up 53% of its $1.65B portfolio in Q4 2013.
- HealthCor Management opened 16 new positions and closed 25 in Q4 2013.
- HealthCor Management's portfolio value fell 12% quarter-over-quarter to $1.65B.
Based on HealthCor Management's 13F filing for Q4 2013, filed 14 Feb 2014.